Safety profile of recombinant canarypox HIV vaccines

Guy De Bruyn, Anthony J. Rossini, Ya Lin Chiu, Drienna Holman, Marnie L. Elizaga, Sharon E. Frey, Donald Burke, Thomas G. Evans, Lawrence Corey, Michael C. Keefer

Research output: Contribution to journalArticle

Abstract

Attenuated poxviruses have been developed for use as candidate vaccine vectors. ALVAC, a strain of the Avipoxvirus canarypox, has been extensively evaluated as a vector for vaccines against the human immunodeficiency virus type 1 (HIV-1). This report presents the safety and reactogenicity data derived from 11 multicenter, randomized controlled trials of ALVAC-HIV vaccines conducted by the HIV Vaccine Trials Network (HVTN) and its predecessor, the AIDS Vaccine Evaluation Group (AVEG). Five different ALVAC vaccine constructs were tested among 1497 volunteers. Reactogenicity was similar for different ALVAC constructs. Local reactions of any grade to ALVAC vaccines were common. However, fewer than 2% of vaccinees had severe local responses, and less than 1% experienced severe local pain or tenderness. Systemic responses were mild and transient. As combination vaccine regimens are in common use, we also evaluated side effects of ALVAC vectors given in combination with a recombinant subunit protein. No significant differences were noted in the reactogenicity of ALVAC given with or without a recombinant envelope subunit vaccine. Black, non-Hispanic and male recipients of ALVAC-HIV reported less pain following vaccination than White, non-Hispanics and females, respectively. ALVAC-HIV vaccines are well tolerated at tested doses. The reactogenicity profiles are comparable to those reported for existing vaccines licensed for use among adults. Reactogenicity does not appear to be related to the number or type of inserted genes, and did not vary between different ALVAC constructs.

Original languageEnglish (US)
Pages (from-to)704-713
Number of pages10
JournalVaccine
Volume22
Issue number5-6
DOIs
StatePublished - Jan 26 2004

Fingerprint

AIDS Vaccines
vaccines
Safety
Vaccines
Avipoxvirus
Poxviridae
Combined Vaccines
vector vaccines
Pain
Subunit Vaccines
Recombinant Proteins
HIV-1
pain
Volunteers
Vaccination
Randomized Controlled Trials
ALVAC vaccine
subunit vaccines
protein subunits
Human immunodeficiency virus 1

Keywords

  • Canarypox
  • Clinical trial
  • HIV
  • Reactogenicity
  • Safety
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

De Bruyn, G., Rossini, A. J., Chiu, Y. L., Holman, D., Elizaga, M. L., Frey, S. E., ... Keefer, M. C. (2004). Safety profile of recombinant canarypox HIV vaccines. Vaccine, 22(5-6), 704-713. https://doi.org/10.1016/j.vaccine.2003.08.023

Safety profile of recombinant canarypox HIV vaccines. / De Bruyn, Guy; Rossini, Anthony J.; Chiu, Ya Lin; Holman, Drienna; Elizaga, Marnie L.; Frey, Sharon E.; Burke, Donald; Evans, Thomas G.; Corey, Lawrence; Keefer, Michael C.

In: Vaccine, Vol. 22, No. 5-6, 26.01.2004, p. 704-713.

Research output: Contribution to journalArticle

De Bruyn, G, Rossini, AJ, Chiu, YL, Holman, D, Elizaga, ML, Frey, SE, Burke, D, Evans, TG, Corey, L & Keefer, MC 2004, 'Safety profile of recombinant canarypox HIV vaccines', Vaccine, vol. 22, no. 5-6, pp. 704-713. https://doi.org/10.1016/j.vaccine.2003.08.023
De Bruyn G, Rossini AJ, Chiu YL, Holman D, Elizaga ML, Frey SE et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine. 2004 Jan 26;22(5-6):704-713. https://doi.org/10.1016/j.vaccine.2003.08.023
De Bruyn, Guy ; Rossini, Anthony J. ; Chiu, Ya Lin ; Holman, Drienna ; Elizaga, Marnie L. ; Frey, Sharon E. ; Burke, Donald ; Evans, Thomas G. ; Corey, Lawrence ; Keefer, Michael C. / Safety profile of recombinant canarypox HIV vaccines. In: Vaccine. 2004 ; Vol. 22, No. 5-6. pp. 704-713.
@article{acd0d0cab1cc43e8a48d0e170d62df53,
title = "Safety profile of recombinant canarypox HIV vaccines",
abstract = "Attenuated poxviruses have been developed for use as candidate vaccine vectors. ALVAC, a strain of the Avipoxvirus canarypox, has been extensively evaluated as a vector for vaccines against the human immunodeficiency virus type 1 (HIV-1). This report presents the safety and reactogenicity data derived from 11 multicenter, randomized controlled trials of ALVAC-HIV vaccines conducted by the HIV Vaccine Trials Network (HVTN) and its predecessor, the AIDS Vaccine Evaluation Group (AVEG). Five different ALVAC vaccine constructs were tested among 1497 volunteers. Reactogenicity was similar for different ALVAC constructs. Local reactions of any grade to ALVAC vaccines were common. However, fewer than 2{\%} of vaccinees had severe local responses, and less than 1{\%} experienced severe local pain or tenderness. Systemic responses were mild and transient. As combination vaccine regimens are in common use, we also evaluated side effects of ALVAC vectors given in combination with a recombinant subunit protein. No significant differences were noted in the reactogenicity of ALVAC given with or without a recombinant envelope subunit vaccine. Black, non-Hispanic and male recipients of ALVAC-HIV reported less pain following vaccination than White, non-Hispanics and females, respectively. ALVAC-HIV vaccines are well tolerated at tested doses. The reactogenicity profiles are comparable to those reported for existing vaccines licensed for use among adults. Reactogenicity does not appear to be related to the number or type of inserted genes, and did not vary between different ALVAC constructs.",
keywords = "Canarypox, Clinical trial, HIV, Reactogenicity, Safety, Vaccine",
author = "{De Bruyn}, Guy and Rossini, {Anthony J.} and Chiu, {Ya Lin} and Drienna Holman and Elizaga, {Marnie L.} and Frey, {Sharon E.} and Donald Burke and Evans, {Thomas G.} and Lawrence Corey and Keefer, {Michael C.}",
year = "2004",
month = "1",
day = "26",
doi = "10.1016/j.vaccine.2003.08.023",
language = "English (US)",
volume = "22",
pages = "704--713",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "5-6",

}

TY - JOUR

T1 - Safety profile of recombinant canarypox HIV vaccines

AU - De Bruyn, Guy

AU - Rossini, Anthony J.

AU - Chiu, Ya Lin

AU - Holman, Drienna

AU - Elizaga, Marnie L.

AU - Frey, Sharon E.

AU - Burke, Donald

AU - Evans, Thomas G.

AU - Corey, Lawrence

AU - Keefer, Michael C.

PY - 2004/1/26

Y1 - 2004/1/26

N2 - Attenuated poxviruses have been developed for use as candidate vaccine vectors. ALVAC, a strain of the Avipoxvirus canarypox, has been extensively evaluated as a vector for vaccines against the human immunodeficiency virus type 1 (HIV-1). This report presents the safety and reactogenicity data derived from 11 multicenter, randomized controlled trials of ALVAC-HIV vaccines conducted by the HIV Vaccine Trials Network (HVTN) and its predecessor, the AIDS Vaccine Evaluation Group (AVEG). Five different ALVAC vaccine constructs were tested among 1497 volunteers. Reactogenicity was similar for different ALVAC constructs. Local reactions of any grade to ALVAC vaccines were common. However, fewer than 2% of vaccinees had severe local responses, and less than 1% experienced severe local pain or tenderness. Systemic responses were mild and transient. As combination vaccine regimens are in common use, we also evaluated side effects of ALVAC vectors given in combination with a recombinant subunit protein. No significant differences were noted in the reactogenicity of ALVAC given with or without a recombinant envelope subunit vaccine. Black, non-Hispanic and male recipients of ALVAC-HIV reported less pain following vaccination than White, non-Hispanics and females, respectively. ALVAC-HIV vaccines are well tolerated at tested doses. The reactogenicity profiles are comparable to those reported for existing vaccines licensed for use among adults. Reactogenicity does not appear to be related to the number or type of inserted genes, and did not vary between different ALVAC constructs.

AB - Attenuated poxviruses have been developed for use as candidate vaccine vectors. ALVAC, a strain of the Avipoxvirus canarypox, has been extensively evaluated as a vector for vaccines against the human immunodeficiency virus type 1 (HIV-1). This report presents the safety and reactogenicity data derived from 11 multicenter, randomized controlled trials of ALVAC-HIV vaccines conducted by the HIV Vaccine Trials Network (HVTN) and its predecessor, the AIDS Vaccine Evaluation Group (AVEG). Five different ALVAC vaccine constructs were tested among 1497 volunteers. Reactogenicity was similar for different ALVAC constructs. Local reactions of any grade to ALVAC vaccines were common. However, fewer than 2% of vaccinees had severe local responses, and less than 1% experienced severe local pain or tenderness. Systemic responses were mild and transient. As combination vaccine regimens are in common use, we also evaluated side effects of ALVAC vectors given in combination with a recombinant subunit protein. No significant differences were noted in the reactogenicity of ALVAC given with or without a recombinant envelope subunit vaccine. Black, non-Hispanic and male recipients of ALVAC-HIV reported less pain following vaccination than White, non-Hispanics and females, respectively. ALVAC-HIV vaccines are well tolerated at tested doses. The reactogenicity profiles are comparable to those reported for existing vaccines licensed for use among adults. Reactogenicity does not appear to be related to the number or type of inserted genes, and did not vary between different ALVAC constructs.

KW - Canarypox

KW - Clinical trial

KW - HIV

KW - Reactogenicity

KW - Safety

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=9144251565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144251565&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2003.08.023

DO - 10.1016/j.vaccine.2003.08.023

M3 - Article

C2 - 14741163

AN - SCOPUS:9144251565

VL - 22

SP - 704

EP - 713

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 5-6

ER -